Cypher shows promise for bifurcated lesions
This article was originally published in Clinica
Executive Summary
Johnson & Johnson's sirolimus-eluting stent, Cypher, has shown positive results when used in patients with coronary bifurcation lesions, the treatment of which is currently associated with a challenging procedure and unfavourable long-term clinical and angiographic outcome.